Compare TGTX & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | LEA |
|---|---|---|
| Founded | 1993 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.2B |
| IPO Year | 2008 | 1994 |
| Metric | TGTX | LEA |
|---|---|---|
| Price | $55.33 | $139.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $49.80 | ★ $132.21 |
| AVG Volume (30 Days) | ★ 2.5M | 535.3K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | 0.12 | ★ 3.34 |
| Revenue | $2,785,000.00 | ★ $23,259,100,000.00 |
| Revenue This Year | $49.08 | $2.50 |
| Revenue Next Year | $26.69 | $3.12 |
| P/E Ratio | $459.33 | ★ $40.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $91.67 |
| 52 Week High | $59.30 | $150.33 |
| Indicator | TGTX | LEA |
|---|---|---|
| Relative Strength Index (RSI) | 60.43 | 55.96 |
| Support Level | $28.57 | $139.14 |
| Resistance Level | $57.38 | $141.92 |
| Average True Range (ATR) | 2.40 | 3.16 |
| MACD | -0.54 | 0.43 |
| Stochastic Oscillator | 51.47 | 90.20 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.